[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Onconic Therapeutics Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":183},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,47,73,95,114,136,162],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100636784","phase-1-food-and-ethnicity-effects-on-pharmacokinetics-and-safety-of-jpi-547-in-healthy-male-participants-100636784",false,"NCT07570186","Food and Ethnicity Effects on Pharmacokinetics and Safety of JPI-547 in Healthy Male Participants","A Randomized, Open-label, Single-dose, Crossover Phase 1 Clinical Trial to Evaluate the Effects of Food or Ethnicity on the Pharmacokinetics and Safety\u002FTolerability of JPI-547 After a Single Oral Administration in Healthy Male Korean, Caucasian and Chinese Participants","Inclusion Criteria:\n\n* Healthy Korean, Caucasian, or Chinese male participants aged 19 to 50 years at screening\n* Body weight between 50.0 and 90.0 kg and BMI between 18.5 and 29.9 kg\u002Fm²\n* Able to understand the study and provide written informed consent\n* Considered suitable for study participation by the investigator based on medical history, physical examination, and clinical laboratory tests\n\nExclusion Criteria:\n\n* Clinically significant medical or surgical history\n* Gastrointestinal disease or surgery affecting drug absorption\n* Hypersensitivity to PARP inhibitors or other significant drug allergy\n* Drug abuse history or positive drug screening\n* Clinically significant abnormal vital signs or laboratory results\n* Positive viral or serologic screening tests\n* Recent use of prohibited medications\n* Recent participation in another clinical trial\n* Recent blood donation or transfusion\n* Inability to abstain from smoking, alcohol, caffeine, or grapefruit\n* Failure to comply with contraception or sperm donation requirements\n* Any condition making the participant unsuitable in the investigator's judgment",true,"MALE","19 Years","50 Years",{"count":21,"type":22},36,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","This study aims to evaluate the effects of food or ethnicity on the pharmacokinetics and safety\u002Ftolerability of JPI-547 after a single oral administration in healthy male Korean, Caucasian, and Chinese participants.",[28],"Healthy Volunteers",[30,31,32,33],"JPI-547","Food Effect","Ethnicity","Pharmacokinetics","NOT_YET_RECRUITING","2026-04-29",{"date":37,"type":38},"2026-05-06","ACTUAL",{"date":40,"type":22},"2026-05",{"date":42,"type":22},"2026-07",{"name":44,"class":45},"Onconic Therapeutics Inc.","INDUSTRY",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":54,"minAge":18,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100459082","phase-1-study-to-assess-the-safety-tolerability-of-jpi-547-in-combination-with-modified-folfirinox-or-gemcitabine-nab-paclitaxel-in-patients-with-locally-advanced-and-metastatic-pancreatic-cancer-100459082","NCT05257993","Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer","An Open-label, Dose-finding, Phase Ib\u002FII Study to Assess the Safety, Tolerability of JPI-547, a Dual Inhibitor of PARP\u002FTankyrase, in Combination With Modified FOLFIRINOX (mFOLFIRINOX) or Gemcitabine-nab-paclitaxel (GemAbraxne) in Patients With Locally Advanced and Metastatic Pancreatic Cancer","Inclusion Criteria:\n\n\\[Phase 1b\u002F2\\]\n\n1. Histologically or cytologically confirmed inoperable locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC)\n2. Those with at least one measurable lesion in accordance with RECIST 1.1\n3. Those with Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n4. Those with an expected survival period ≥12 weeks\n5. Patients with adequate hematologic function, renal and hepatic function confirmed by the following criteria (During the screening period, laboratory tests can be retested only once.)\n6. Those who voluntarily decide to participate in this clinical study after hearing sufficient explanations and who consent in writing\n\n\\[only to Phase 2\\]\n\n1\\. Subjects from whom tumor tissue samples can be obtained at screening and who meet at least one of the following criteria:\n\n* Tumor tissue samples stored prior to screening are available\n* Tumor tissue samples can be obtained at screening with the subject's consent to biopsy\n\nExclusion Criteria:\n\n\\[Phase 1b\u002F2\\]\n\n1. Those with a history of severe hypersensitivity to the investigational product or combination anticancer drugs.\n2. Those with the following medical history or surgical history\u002Fprocedural history confirmed\n\n   1. Other primary malignant tumors other than pancreatic cancer\n   2. Major surgery that requires general anesthesia or breathing aid\n   3. Severe cardiovascular disease\n   4. New York Heart Association Class 3 or 4 heart failure\n   5. Severe cerebrovascular disease t\n   6. Pulmonary thrombosis, deep vein thrombosis, or bronchial asthma, obstructive pulmonary disease, and other life-threatening severe lung diseases\n   7. Infections requiring administration of systemic antibiotics or antivirals, etc.\n   8. Hematologic malignancy\n3. Those with the following diseases\n\n   1. Massive ascites, pleural effusions requiring therapeutic paracentesis\n   2. Neuropathy ≥Grade 2\n   3. Diarrhea, chronic inflammatory bowel disease\n   4. Intestinal paralysis, intestinal obstruction\n   5. Diseases that make oral administration difficult or affect absorption\n   6. Interstitial lung disease, pulmonary fibrosis\n   7. Dialysis patient\n   8. Patients with clinically significant symptoms or uncontrolled central nervous system or brain metastases\n\n   j. Uncontrolled hypertension (systolic blood pressure \\> 150 mmHg or diastolic blood pressure \\>90 mmHg) k. Bleeding diatheses l. Active hepatitis B or C virus. m. Known human immunodeficiency virus (HIV) positive\n4. Those with a medication history of the following drugs\n\n   1. Anti-cancer drug therapy such as chemotherapy and biological therapy\n   2. Radiation therapy within 2 weeks of baseline\n   3. Those who are taking or expected to require administration of strong inhibitors or inducers of CYP3A4\n   4. (For mFOLFIRINOX cohort) Those who are taking or expected to require administration of sorivudine\n   5. Patients who require continuous administration of non-steroidal anti-inflammatory drugs (NSAIDs) with high bleeding risk\n   6. Patients requiring continuous administration of systemic corticosteroid equivalent to prednisone \\>10 mg\u002Fday\n   7. Those who have received antithrombotic agents, including antiplatelet agents, anticoagulants, etc.\n5. Pregnant women, lactating women, or women of childbearing potential and men who do not intend to practice abstinence or use appropriate contraceptive methods for until 6 months for men and 9 months for women after administration of the investigational product and during the clinical study\n6. Those who have administered other investigational products or have received investigational medical device procedures within 4 weeks of the baseline\n7. Other patients who are inappropriate or unable to participate in this clinical study at the discretion of the investigator","ALL","79 Years",{"count":57,"type":22},71,[25,59],"PHASE2","The purpose of this study is to assess the safety, tolerability and efficacy of JPI-547 in combination with modified FOLFIRINOX (mFOLFIRINOX) or Gemcitabine-nab-paclitaxel (GemAbraxne) in patients with locally advanced and metastatic pancreatic cancer",[62],"Pancreatic Ductal Adenocarcinoma","RECRUITING","2026-04-08",{"date":66,"type":38},"2026-04-13",{"date":68,"type":38},"2022-03-30",{"date":70,"type":22},"2030-04",{"name":44,"class":45},4,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":80,"minAge":18,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":23,"phases":83,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":46},"100621453","phase-2-to-evaluate-the-efficacy-and-safety-of-jpi-547-in-combination-with-bevacizumab-as-maintenance-therapy-in-relapsed-ovarian-cancer-100621453","NCT07370818","To Evaluate the Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Maintenance Therapy in Relapsed Ovarian Cancer","An Open-label, Dose-finding and Randomized Active-controlled, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of JPI-547 With Bevacizumab Maintenance Therapy in Relapsed Ovarian Cancer Patients Previously Treated With PARP Inhibitor Maintenance Therapy and Responding to Last Platinum Chemotherapy","Inclusion Criteria:\n\n* Histologically or cytologically confirmed recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer \\[High-grade serous carcinoma (HGSC), Grade 2\u002F3 endometrioid carcinoma\\]\n* Patients whose BRCA 1\u002F2 gene mutation status and\u002For Homologous Recombination Deficiency (HRD) status.\n* Patients who received platinum-based chemotherapy followed by PARP inhibitor maintenance therapy,\n* Patients who had received chemotherapy before participating in the clinical trial and responded to platinum-based chemotherapy.\n* Those with Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.\n* Individuals with confirmed adequate hematological, renal, and hepatic function (laboratory tests may be repeated once during the screening period)\n\nExclusion Criteria:\n\n* Patients with a history of severe drug hypersensitivity or hypersensitivity to the investigational drug, its components, or drugs within the same class.\n* Individuals with dysphagia\n* Patients with a confirmed specific medical history or a past surgical history.\n* Patients with specific comorbidities or medical abnormalities.\n* Pregnant women, lactating women, or women of childbearing potential who do not agree to use appropriate contraception during the clinical trial period and for 24 weeks after administration of the investigational medicinal product.\n* Those who have administered other investigational products or have received investigational medical device procedures within 4 weeks of the baseline\n* Other patients who are inappropriate or unable to participate in this clinical study at the discretion of the investigator.","FEMALE",{"count":82,"type":22},81,[59],"This study aims to to evaluate the efficacy, safety, and pharmacokinetics of JPI- 547 with bevacizumab maintenance therapy in relapsed ovarian cancer patients",[86],"Ovarian Cancer","2026-01-21",{"date":89,"type":38},"2026-01-27",{"date":91,"type":22},"2026-02-27",{"date":93,"type":22},"2031-12-31",{"name":44,"class":45},{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":54,"minAge":18,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":23,"phases":104,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":111,"leadSponsor":113,"locationsCount":46},"100620961","phase-1-to-evaluate-the-safety-and-tolerability-of-study-drug-as-a-third-line-and-beyond-therapy-for-recurrent-or-metastatic-gastric-cancer-100620961","NCT07364422","To Evaluate the Safety and Tolerability of Study Drug as a Third-line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer","A Multicenter, Open-label, Single-arm, Dose-finding and Expansion Phase 1b\u002F2 Study to Evaluate the Safety and Tolerability of JPI-547 in Combination With Irinotecan as a Third Line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer","Inclusion Criteria:\n\n* Patients with recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma who have progressed after second-line therapy.\n* Those with Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n* Those with at least one measurable lesion in accordance with RECIST 1.1\n\nExclusion Criteria:\n\n* Patients with a confirmed specific medical history or past surgical history\n* Patients who meet specific criteria regarding prior treatment\n* Patients with a history of specific drug administration\n* Patients with specific comorbidities.\n* Patients who have undergone major surgery within 4 weeks prior to screening or are expected to require major surgery during the clinical trial are excluded. (However, those who have had minor surgeries\n* Patients with symptoms at the time of screening, who have not received treatment, or who have rapidly progressing central nervous system (CNS) metastases.\n* Patients with mental disorders or altered mental status\u002Fconsciousness (AMS) that impair their ability to understand this clinical trial for informed consent.\n* Pregnant or Lactating Women\n* Subjects with a history of severe allergic anaphylactic reactions to the investigational product and\u002For its components, or who have contraindications to the administration of the investigational product and\u002For irinotecan\n* Patients considered unsuitable for this clinical trial by the investigator.",{"count":103,"type":22},49,[25,59],"This study aims to evaluate the safety and tolerability of JPI-547 in combination with irinotecan as a third-line and beyond therapy for recurrent or metastatic gastric cancer",[107],"Gastric Cancer (GC)",{"date":109,"type":38},"2026-01-23",{"date":91,"type":22},{"date":112,"type":22},"2029-02-28",{"name":44,"class":45},{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":16,"sex":54,"minAge":18,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":23,"phases":124,"briefSummary":125,"conditions":126,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":46},"100613352","phase-1-to-evaluate-the-safety-and-the-pharmacokinetic-and-pharmacodynamic-interactions-between-jp-1366-and-clopidogrel-aspirin-atorvastatin-and-apixaban-100613352","NCT07265466","to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban","A Phase 1 Clinical Trial to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban in Healthy Volunteers.","Inclusion Criteria:\n\n* Healthy subject aged ≥ 19 years to \\\u003C 65 years at the time of screening\n* Subjects who weigh ≥ 50 kg (or ≥ 45 kg in the case of females) with body mass index (BMI) of ≥ 18.0 kg\u002Fm2 and ≤ 30.0 kg\u002Fm2\n* Subjects who have voluntarily decided to participate after fully understanding the clinical trial based on the detailed explanation given, and have provided written informed consent before the screening procedure.\n\nExclusion Criteria:\n\n* Subject who has a clinically significant history of disease in the liver, kidneys, digestive system, respiratory system, musculoskeletal system, endocrine system, neuropsychiatric system, hematopoietic and oncological system, or cardiovascular system.\n* The Subject who has a clinically significant bleeding or a history of congenital or acquired bleeding disorders such as hemophilia\n* Subject who has a history of gastrointestinal disorders (e.g., Crohn's disease, ulcerative disease, etc.) or surgery (excluding appendectomy, hernia repair, endoscopic polypectomy, or hemorrhoidectomy, fissure, or fistula surgery) that may affect the absorption of the investigational product.\n* The subject who has a hereditary disorder (galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption etc.).\n* Screening laboratory test showing any of the following abnormal laboratory results\n* Subjects who are judged unsuitable to participate in the study in the opinion of the investigator","64 Years",{"count":123,"type":22},96,[25],"to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban",[127],"Drug Drug Interaction (DDI)","2025-12-02",{"date":130,"type":38},"2025-12-04",{"date":132,"type":38},"2025-11-17",{"date":134,"type":22},"2026-03-30",{"name":44,"class":45},{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":54,"minAge":18,"maxAge":143,"enrollmentInfo":144,"targetDuration":4,"studyType":23,"phases":146,"briefSummary":148,"conditions":149,"keywords":151,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":4},"100605305","phase-3-phase-3-study-of-jp-1366-efficacy-and-safety-of-jp-1366-in-patients-with-non-erosive-gastroesophageal-reflux-disease-100605305","NCT07160790","Phase 3 Study of JP-1366: Efficacy and Safety of JP-1366 in Patients With Non-erosive Gastroesophageal Reflux Disease","Efficacy and Safety of JP-1366 in Patients With Non-erosive Gastroesophageal Reflux(NERD) Disease: Double-blind, Randomized","Inclusion Criteria:\n\n* Subjects who have experienced both heartburn and acid regurgitation\n* Subjects in whom no mucosal breaks were observed on upper GI endoscopy at Visit 1 by LA Classification\n* Subjects who fully understand this clinical trial and voluntarily signed the informed consent form\n\nExclusion Criteria:\n\n* Subjects who have significant gastrointestinal diseases or procedures affecting the esophagus, stomach, or duodenum\n* Subjects who have a history of recent substance abuse, malignancy, systemic autoimmune or immune deficiency diseases, refractory response to PPI\u002FP-CAB, hypersensitivity to study drugs, genetic metabolic disorders, or significant psychiatric conditions.\n* Subjects who showed clinically significant abnormalities in laboratory tests\n* Positive result in the H. pylori test\n* Pregnant or breast-feeding women\n* Subjects who require hospitalization are scheduled to undergo surgery during the study period, or have undergone major surgery requiring general anesthesia\n* Other people deemed unsuitable for participation in this study according to the medical opinion of the investigator","75 Years",{"count":145,"type":22},321,[147],"PHASE3","This study aims to evaluate the efficacy and safety of JP-1366 in Patients with NERD",[150],"Non-erosive Gastroesophageal Reflux Disease",[152,153],"Non-erosive Reflux Disease","Non-Erosive Gastro-Esophageal Reflux Disease","2025-08-29",{"date":156,"type":38},"2025-09-08",{"date":158,"type":22},"2025-09-02",{"date":160,"type":22},"2026-06-30",{"name":44,"class":45},{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":54,"minAge":18,"maxAge":4,"enrollmentInfo":169,"targetDuration":4,"studyType":23,"phases":171,"briefSummary":172,"conditions":173,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":46},"100549861","phase-3-study-to-evaluate-the-efficacy-and-safety-of-jp-1366-in-the-prevention-of-nsaids-induced-peptic-ulcers-100549861","NCT06439563","Study to Evaluate the Efficacy and Safety of JP-1366 in the Prevention of NSAIDs-Induced Peptic Ulcers","A Multicenter, Parallel, Double-blind, Randomized, Active-controlled, Non-inferiority, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of JP-1366 Treatment in the Prevention of (NSAIDs)-Induced Peptic Ulcers","Inclusion Criteria:\n\n1. Adult male\u002Ffemale aged 19 years or older as of the date of obtaining consent\n2. Those who are diagnosed with musculoskeletal diseases such as rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, or other diseases at the time of screening and require continuous administration of NSAIDs for 24 weeks or more\n3. Those with one or more of the following risk factors for ulcer development at the time of screening\n4. Subjects who fully understand this study and voluntarily signed the informed consent form.\n\nExclusion Criteria:\n\n1. Those who cannot undergo upper gastrointestinal endoscopy\n2. At the time of screening, those who were confirmed to have active stage ulcers (A1, A2) or healing stage ulcers (H1, H2) in the stomach or duodenum according to the Sakita-Miwa Classification\\*\n3. Those with a confirmed history of malignant tumor within 5 years\n4. Those with a confirmed history of signal symptoms suggestive of malignant disease of the gastrointestinal tract\n5. Those who need to continuously take corticosteroids, antiplatelet agents, and anticoagulants during this study (however, the following cases are permitted):\n6. Pregnant and lactating women or those with a positive pregnancy test result at screening\n7. Those who participated in another study and were administered investigational products or had medical devices applied at least once within 4 weeks from the screening visit(Visit 0)",{"count":170,"type":22},364,[147],"The sutdy aims to to demonstrate the non-inferiority of JP-1366 10 mg compared to Lanston Capsule 15 mg in preventing NSAIDs-induced peptic ulcers and to compare\u002Fevaluate the efficacy and safety of JP-1366 10 mg.",[174],"Peptic Ulcer","2024-10-30",{"date":177,"type":38},"2024-11-01",{"date":179,"type":38},"2024-10-22",{"date":181,"type":22},"2027-12",{"name":44,"class":45},""]